Abstract
Screening is defined as the presumptive identification of unrecognized disease by means of tests, examinations, or other procedures that can be applied rapidly. The World Health Organization outlines a number of important prerequisites to justify implementation of an effective screening program: Target cancer should have a high prevalence and be associated with a high mortality and morbidity; the screening test has to be safe, effective, and acceptable; the compliance of the target population in attending initial screening and diagnosis and in follow-up visits has to be high; effective treatment should be available to be delivered to screen positive cases; an ideal screening test is one which detects a high percentage of cancers [sensitivity] and has low false-positive rate so that disease-free women are not subjected to unnecessary diagnostic tests. A high prevalence of cancer in the target population being screened is an important prerequisite since even the best screening test will be ineffective when deployed in a population with a low prevalence of cancer. National and/or professional or regulatory body guidelines in individual countries for cancer screening should be based on cancer incidence and prevalence statistics. These need to address at what age and how frequent screening needs to be performed; additional influencing factors to be taken into consideration will also include cost-effectiveness of screening strategy. Quality control and assurance to ensure effectiveness, accuracy, and consistency has to be applied to and monitored for health-care personnel performing and interpreting these tests as well as for the equipment used for this purpose. A tested and a robust referral system for women testing positive for cancers needs to be in place. An information system that can send out invitations for initial screening, follow-up visits, and repeat screening at predetermined intervals is a must to ensure success.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
World Health Organization. Screening for various cancers. http://www.who.int/cancer/detection/variouscancer/en/index.html.
Fletcher SW, Elmore JG. Clinical practice: mammographic screening for breast cancer. N Engl J Med. 2003;348:1672–80.
Tabár L, Fagerberg CJG, Gad A, et al. Reduction in mortality from breast cancer after mass screening with mammography: randomized trial from the breast cancer screening working group of the Swedish national board of health and welfare. Lancet. 1985;1:829–32.
Tabar L, Fagerberg G, Chen HH, et al. Efficacy of breast cancer screening by age. New results from the Swedish two county trials. Cancer. 1995;75:2507–17.
Tabar L, Vitak B, Chen H-H, Yen MF, Duffy SW, Smith RA. Beyond randomized controlled trials: organized mammographic screening substantially reduces breast carcinoma mortality. Cancer. 2001;91(9):1724–31.
Carney PA, Miglioretti DL, Yankaskas BC, et al. Individual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of mammography. Ann Intern Med. 2003;138:168–75.
Perry N, Broeders M, Wolf CD, Tornberg S, Holland R, Karsa LV. European guidelines for quality assurance in breast cancer screening and diagnosis. Fourth edition-summary document. Ann Oncol. 2008;19:614–22.
Lee CH, Dershaw DD, Kopans D, Evans P, Monsees B, Monticello D, et al. Breast cancer screening with imaging: recommendations from the society of breast imaging and the ACR on the use of mammography, breast MRI, breast ultrasound, and other technologies for the detection of clinically occult breast cancer. J Am Coll Radiol. 2010;7:18–27.
Elmore JG, Armstrong K, Lehman CD, Fletcher SW. Screening for breast cancer. JAMA. 2005;293(10):1245–56.
Humphrey LL, Helfand M, Chan BKS, Woolf SH. Breast cancer screening: a summary of the evidence. Ann Intern Med. 2002;137:347–60.
Medical Advisory secretariat. Screening mammography for women aged 40 to 49 years at average risk for breast cancer: an evidence-based analysis. Ont Health Technol Assess Ser. 2007;7(1):1–32.
Larsson LG, Andersson I, Bjurstam N, Fagerberg G, Frisell J, Tabár L, Nyström L. Updated overview of the Swedish randomized trials on breast cancer screening with mammography: age group 40–49 at randomization. J Natl Cancer Inst Monogr. 1997;22:57–61.
Malmgren J, Parikh JA, Atwood MK, Kaplan HJ. Impact of mammography detection on the course of breast cancer in women aged 40–49 years. Radiology. 2012;262(3):797–806.
Kerlikowske K, Grady D, Barclay J, Sickles EA, Eaton A, Ernster V. Positive predictive value of screening mammography by age and family history of breast cancer. JAMA. 1993;270(20):2444–50.
Woloshin S, Schwartz LM. The benefits and harms of mammography screening. Understanding the trade-offs. JAMA. 2010;303(2):164–5.
Berg WA. Benefits of screening mammography. JAMA. 2010;303(2):168–9.
Geller BM, Bogart A, Carney PA, Elmore JG, Monsees BS, Miglioretti DL. Is confidence of mammographic assessment a good predictor of accuracy? AJR Am J Roentgenol. 2012;199(1):W134–41.
Marmot MG, Altman DG, Cameron DA, Dewar JA, Thompson SG, Wilcox M. The benefits and harms of breast cancer screening: an independent review. Br J Cancer. 2013;108(11):2205–40.
Bleyer A, Welch HG. Effect of three decades of screening mammography on breast-cancer incidence. N Engl J Med. 2012;367(21):1998–2005.
Gøtzsche PC, Jørgensen KJ. Screening for breast cancer with mammography. Cochrane Database Syst Rev. 2013;(6):CD001877.
Kuhl CK. The “coming of age” of nonmammographic screening for breast cancer. JAMA. 2008;299:2203–5.
Berg WA, Blume JD, Cormack JB, et al. Combined screening with ultrasound and mammography vs mammography alone in women with elevated risk of breast cancer. JAMA. 2008;299:2151–63.
Nothacker M, Duda V, Hahn M, et al. Early detection of breast cancer: benefits and risks of supplemental breast ultrasound in asymptomatic women with mammographically dense breast tissue: a systematic review. BMC Cancer. 2009;9:1–9.
Le-Petross HT, Shetty MK. Magnetic resonance imaging and breast ultrasonography as an adjunct to mammographic screening in high-risk patients. Semin Ultrasound CT MR. 2011;32(4):266–72.
Berg WA. Beyond standard mammographic screening: mammography at age extremes, ultrasound, and MR imaging. Radiol Clin North Am. 2007;45:895–906.
Gordan PB. Ultrasound for breast cancer screening and staging. Radiol Clin North Am. 2002;40:431–41.
Boyd NF, Guo H, Martin LJ, et al. Mammographic density and the risk and detection of breast cancer. N Engl J Med. 2007;356:227–36.
Berg WA. Supplemental screening sonography in dense breasts. Radiol Clin North Am. 2004;42:845–51.
Tohno E, Ueno E, Watanabe H. Ultrasound screening of breast cancer. Breast Cancer. 2009;16:18–22.
Tunoda H, Tohno E, Ueno E, et al. Examination of effectiveness of breast cancer detection by modalities and age groups. J Jpn Ass Breast Cancer Screen. 1998;7:281–5.
Osako T, Takahashi K, Iwase T, et al. Diagnostic ultrasonography and mammography for invasive and noninvasive breast cancer in women aged 30 to 39 years. Breast Cancer. 2007;14:229–33.
Corsetti V, Ferrari A, Ghirardi M, et al. Role of ultrasonography in detecting mammographically occult breast carcinoma in women with dense breasts. Radiol Med (Torino). 2006;111:440–8.
Menell JH, Morris EA, Dershaw DD, et al. Determination of the presence and extent of pure ductal carcinoma in situ by mammography and magnetic resonance imaging. Breast J. 2005;11:382–90.
Hooley RJ, et al. Screening US in patients with mammographically dense breasts: initial experience with Connecticut Public Act 09–41. Radiology. 2012;265(1):59–69.
Weigert J, Steenbergen S. The Connecticut experiment: the role of ultrasound in the screening of women with dense breasts. Breast J. 2012;18(6):517–22.
Corsetti V. Evidence of the effect of adjunct ultrasound screening in women with mammography-negative dense breasts: interval breast cancers at 1 year follow-up. Eur J Cancer. 2011;47(7):1021–6.
Gartlehner G, et al. Adjunct ultrasonography for breast cancer screening in women at average risk: a systematic review. Int J Evid Based Health. 2013;11(2):87–93.
Gartlehner G. Mammography in combination with breast ultrasonography versus mammography for breast cancer screening in women at average risk. Cochrane Database Syst Rev. 2013;(4):CD009632.
D’Orsi CJ, Newell MS. On the frontline of screening for breast cancer. Semin Oncol. 2011;38(1):119–27.
Meissner HI, Breen N, Yabroff KR. Whatever happened to clinical breast examination. Am J Prev Med. 2003;25(3):259–63.
Weiss NS. Breast cancer mortality in relation to clinical breast examination and breast self examination. Breast J. 2003;9 suppl 2:S86–9.
Barton MB, Harris R, Fletcher SW. Does this patient have breast cancer? The screening clinical breast examination: should it be done? How? JAMA. 1999;282:1270–80.
Miller AB, To T, Baines CJ, Wall C. Canadian National Breast Screening Study-2: 13-year results of a randomized trial in women aged 50–59 years. Natl Cancer Inst. 2000;92:1490–9.
Okonkwo QL, Draisma G, Kinderen AD, et al. Breast cancer screening policies in developing countries: a cost effectiveness analysis for India. J Natl Cancer Inst. 2008;100:1290–300.
Kearney AJ, Murray M. Breast cancer screening recommendations: is mammography the only answer? J Midwifery Womens Health. 2009;54:393–400.
Thomas DB, Gao DL, Ray RM, et al. Randomized trial of breast self-examination in Shanghai: final results. J Natl Cancer Inst. 2002;94:1445–57.
Gastrin G, et al. Incidence and mortality from breast cancer in the Mama program for breast screening in Finland, 1973–1986. Cancer. 1994;73:2168–74, c J. 157, 1205–1212.
Semiglazov VF, et al. Study of the role of breast self-examination in the reduction of mortality from breast cancer. Eur J Cancer. 1993;29A:2039–46.
O’Malley MS, Fletcher SW, US Preventive Services Task Force. Screening for breast cancer with breast self-examination: a critical review. JAMA. 1987;257:2196–203.
Miller AB, Bianes CJ. The role of clinical breast examination and breast self-examination. Prev Med. 2011;53:118–20.
Harvey BJ, et al. Effect of breast self-examination techniques on the risk of death from breast cancer. Can Med Assoc. 1997;157(9):1205–12.
Hendrick RE. Helvie mammography screening: a new estimate of number needed to screen to prevent one breast cancer death. AJR. 2012;198:723–8.
Demissie K, Mills OF, Rhoads GG. Empirical comparison of the results of randomized controlled trials and case–control studies in evaluating the effectiveness of screening mammography. J Clin Epidemiol. 1998;51:81–91.
Moss SM, Cuckle H, Evans A, et al. Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years’ follow-up: a randomized controlled trial. Lancet. 2006;368:2053–60.
Hendrick RE. Mammography screening: a new estimate of number needed to screen to prevent one breast cancer death. AJR Am J Roentgenol. 2012;198(3):723–8.
Smith-Bindman R, Kerlikowske K, Gebretsadik T. Is screening mammography effective in elderly women? Am J Med. 2000;108:112–9.
Mandelblatt J, et al. Which strategies reduce breast cancer mortality most? Collaborative modeling of optimal screening, treatment, and obesity prevention. Cancer. 2013;119(14):2541–8.
Webb ML, Cady B, Michaelson JS, Bush DM, Calvillo KZ, Kopans DB, Smith BL. A failure analysis of invasive breast cancer. Cancer. 2013. doi:10.1002/cncr.28199 [Epub ahead of print].
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Science+Business Media New York
About this chapter
Cite this chapter
Shetty, M.K. (2015). Screening for Breast Cancer. In: Shetty, M. (eds) Breast Cancer Screening and Diagnosis. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-1267-4_2
Download citation
DOI: https://doi.org/10.1007/978-1-4939-1267-4_2
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4939-1266-7
Online ISBN: 978-1-4939-1267-4
eBook Packages: MedicineMedicine (R0)